Column

  • Your Selections:

Refine Results

date

Type

Topics

Tags

The Sleeper Health Cost Policy

In this Axios column, Drew Altman unpacks President Biden’s recent executive order on promoting competition, exploring its significance for new efforts to control health costs by addressing consolidation in the health care industry.

Why Drug Price Negotiation Has Staying Power

In this Axios column, Drew Altman looks beyond Medicare to what’s at stake for employers and workers in the debate about the government negotiating drug prices.

Expanding Medicare to Adults at Age 60 Years—Medicare-for-More?

In this column for the JAMA Health Forum, Larry Levitt examines the implications of lowering Medicare’s age of eligibility, which is emerging as a potential pathway toward Medicare-for-all or a public option among single-payer advocates. He explores the implications for costs, industry, people and broader reform efforts.

Persistent Vaccine Myths

With news that the country has now vaccinated half of its population with at least one dose, This Drew Altman Axios column highlights the persistent COVID-19 vaccine myths that are believed by a substantial portion of the unvaccinated population and discusses the options to address vaccine misinformation.

Corporate Leaders Are Getting Bullish On Government Action On Health Care Costs

In this Axios column, Drew Altman explores whether the long struggle with rising health costs has caused the tide to turn in corporate leaders’ attitudes towards government involvement in controlling health spending and whether it is part of a larger shift in comfort with government action to solve problems.

Where To Start To Build Vaccine Confidence

In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them.” But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of ‘wait and see’ Americans.”

Vaccine Confidence Isn’t The Main Obstacle To Reaching Herd Immunity

In this Axios column, Drew Altman paints a more optimistic picture of the prospects for getting to herd immunity as vaccine confidence grows, but underscores the urgency of building vaccine confidence in Black and Latino communities where barriers to access and good information are obstacles to getting vaccinated.

Seeing Others Vaccinated May Be The Best Cure For Vaccine Hesitancy

In his latest Axios column, Drew Altman shows why vaccine hesitancy will naturally decrease as more and more people see their family members and friends vaccinated without adverse consequences. It’s a hopeful sign about vaccine hesitancy, and should help free up resources to focus on the remaining vaccine hesitant.

Addressing the Risk of Medicare Trust Fund Insolvency

In this Viewpoint for the Journal of the American Medical Association (JAMA), KFF’s Tricia Neuman and co-author Richard G. Frank of Harvard Medical School explain that the looming 2024 insolvency of the Medicare Hospital Insurance Trust Fund cannot be ignored for long.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.